Resistance profile

Low rates of resistance in virologically suppressed adults switching therapy1,2

Study 109: Resistance in virologically suppressed adults who switched to an FTC/TAF-based regimen* vs those who remained on an FTC/TDF-based regimen through Week 481

Resistance mutations Switched to FTC/TAF
+ EVG/COBI
Remained on FTC/TDF
+ 3rd agent
NRTI-resistance mutations 1/959 (<1%) 0/477 (0%)

  • 1 of 10 evaluable virologic failures (n=959) who switched to an FTC/TAF-based regimen* developed treatment-emergent resistance (M184I/M) through Week 481
  • There was no emergent resistance in the comparator arm1
See the Study 109 Study Design

Warnings and precautions (cont'd)

  • Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.

Study 1089: Resistance in virologically suppressed adults who switched to an FTC/TAF + third agent regimen§|| vs those who remained on an FTC/TDF + third agent regimen§|| through Week 482

Resistance mutations Switched to FTC/TAF
+ 3rd agent§||
Remained on FTC/TDF
+ 3rd agent§||
Developed emergent resistance mutations 1/333 (<1%) 0/330 (0%)
  • 1 adult of 333 who switched to an FTC/TAF-based regimen developed emergent resistance (Met184Val reverse transcriptase mutation) and subsequently discontinued treatment (vs 0/330 who remained on an FTC/TDF-based regimen)2
  • There was no emergent resistance in the comparator arm2

See the Study 1089 Study Design

Important Safety Information

BOXED WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs in combination with other antiretrovirals.
  • DESCOVY is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of DESCOVY have not been established in patients coinfected with HIV-1 and HBV. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of DESCOVY. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue DESCOVY. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

Warnings and precautions

  • Fat redistribution or accumulation has been observed in patients receiving antiretroviral therapy.
  • Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.
  • New onset or worsening renal impairment: Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir prodrugs. In clinical trials of emtricitabine and tenofovir alafenamide with elvitegravir and cobicistat, there have been no cases of Fanconi syndrome or proximal renal tubulopathy (PRT). Do not initiate DESCOVY in patients with estimated creatinine clearance (CrCl) <30 mL/min. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue DESCOVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.
    Renal monitoring: In all patients, monitor CrCl, urine glucose, and urine protein prior to initiating and during therapy. In patients with chronic kidney disease, additionally monitor serum phosphorus.
  • Bone loss and mineralization defects: Decreases in bone mineral density (BMD) have been reported with the use of tenofovir prodrugs. Consider monitoring BMD in patients with a history of pathologic fracture or risk factors for bone loss. Mineralization defects, including osteomalacia associated with PRT, have been reported with the use of TDF-containing products.

Adverse reactions

  • Most common adverse reaction (incidence ≥10%; all grades) in clinical studies was nausea (10%).

Drug interactions

  • Prescribing information: Consult the full prescribing information for DESCOVY for more information on potentially significant drug interactions, including clinical comments.
  • Metabolism: Drugs that inhibit P-gp can increase the concentrations of components of DESCOVY. Drugs that induce P-gp can decrease the concentrations of components of DESCOVY, which may lead to loss of efficacy and development of resistance.
  • Drugs affecting renal function: Coadministration of DESCOVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of emtricitabine and tenofovir and the risk of adverse reactions.

Dosage and administration

  • Dosage: Patients 12 years and older (≥35 kg): 1 tablet taken orally once daily with or without food.
  • Renal impairment: Not recommended in patients with CrCl <30 mL/min.
  • Testing prior to initiation: Test patients for HBV infection and assess CrCl, urine glucose and urine protein.

Pregnancy and lactation

  • Pregnancy: There are insufficient data on the use of DESCOVY during pregnancy. In animal studies, no adverse developmental effects were observed with the components of DESCOVY. An Antiretroviral Pregnancy Registry has been established.
  • Lactation: Women infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission.

Indication

DESCOVY® is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients 12 years and older.

Limitations of Use:
DESCOVY is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV-1 infection.

*Administered with EVG + COBI as an STR.
Third agents included EVG + COBI (as an STR), EFV (as an STR), ATV + COBI, or ATV + RTV.1,3
Administered as an STR.
§Patients remained on the following third agents: ATV + RTV, DRV + RTV, LPV + RTV, EFV, NVP, RPV, DTG, RAL, or MVC.2,4
||Adults on boosted PIs (ATV, DRV, and LPV, all boosted with RTV) who were randomly assigned to switch treatment received a fixed combination of 200 mg FTC with 10 mg TAF; those on other third agents received 200 mg FTC with 25 mg TAF.2 In the United States, only 1 dose of DESCOVY (200 mg/25 mg FTC/TAF) is approved for use with any third agent.5


References:

  1. Mills A, Arribas JR, Andrade-Villanueva J, et al; GS-US-292-0109 team. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43-52.
  2. Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3(4):e158-e165.
  3. GENVOYA [package insert]. Gilead Sciences, Inc.; 2016.
  4. Data on file. Gilead Sciences, Inc.
  5. DESCOVY [package insert]. Gilead Sciences, Inc.; 2016.

You are leaving the DESCOVY® website

By following this link, you are leaving www.descovy.com/hcp. This site is not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for the site's content or your use of the site.

By following this link, you are leaving www.descovy.com/hcp